logo-loader
viewKazia Therapeutics Ltd

Kazia Therapeutics gets $1.39 million R&D cash rebate

The company anticipates further data read-outs in calendar 2020, along with the transition of GDC-0084 into a pivotal study for FDA registration.

Kazia Therapeutics Ltd - Kazia Therapeutics gets $1.39 million R&D cash rebate
GDC-0084 is being developed to treat glioblastoma, the most aggressive form of primary brain cancer in adults

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has received $1,390,849 from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending June 30, 2019.

Kazia CEO Dr James Garner said: “The R&D tax rebate is entirely consistent with our forecasts.

“Both GDC-0084 and Cantrixil have had important and value-driving data read-outs during calendar 2019, and the R&D tax rebate will be directly applied to generating further progress in these programs.

“We anticipate further data read-outs in calendar 2020, along with transition of GDC-0084 into a pivotal study for FDA registration.”

GDC-0084 data expected in 1H 2020

GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.

Licensed from Genentech in late 2016, GDC-0084 entered a phase II clinical trial in 2018.

Interim data was reported in November 2019, and further data is expected in 1H 2020.

Quick facts: Kazia Therapeutics Ltd

Price: 0.445 AUD

ASX:KZA
Market: ASX
Market Cap: $32.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Kazia Therapeutics releases data from study of GDC-0084 into...

Kazia Therapeutics Ltd (ASX:KZA) chief executive officer Dr James Garner updates Proactive on the release of positive key interim data from the company's ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of primary brain cancer. Dr Garner explains...

on 25/11/19

2 min read